[1]
JommiC. and CavazzaM. 2019. Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals. Global & Regional Health Technology Assessment. 6, 1 (Jul. 2019). DOI:https://doi.org/10.33393/grhta.2019.460.